AU
CA
NZ
UK
US
IND
Last update at 2026-03-11T14:57:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Harvard Bioscience price target lowered to $3 from $4.50 at Benchmark
Wed 14 May 25, 01:14 PMHarvard Bioscience Announces First Quarter 2025 Financial Results
Mon 12 May 25, 11:00 AMHarvard Bioscience Announces CFO Transition
Thu 10 Apr 25, 08:45 PMTraders are paying attention to the gapping stocks in Tuesday's session.
Tue 08 Apr 25, 04:30 PMHarvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025
Wed 12 Mar 25, 08:00 PMHarvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results
Wed 12 Mar 25, 11:21 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -9.17900M | -0.14000M | -7.29200M | -5.50200M | -8.51500M |
| Minority interest | - | - | - | - | - |
| Net income | -9.51600M | -0.28800M | -7.81000M | -4.68700M | -3.46200M |
| Selling general administrative | 24.49M | 24.30M | 23.51M | 22.76M | 21.38M |
| Selling and marketing expenses | 25.04M | 24.64M | 19.92M | 23.26M | 24.44M |
| Gross profit | 60.82M | 67.65M | 58.04M | 64.32M | 63.18M |
| Reconciled depreciation | 7.58M | 7.62M | 7.63M | 7.73M | 7.88M |
| Ebit | -7.16600M | 1.40M | -0.58500M | 1.47M | -3.29600M |
| Ebitda | -1.04400M | 7.24M | 5.12M | 7.22M | 2.09M |
| Depreciation and amortization | 6.12M | 5.84M | 5.71M | 5.75M | 5.38M |
| Non operating income net other | 0.30M | -0.66600M | -2.68200M | -0.46900M | -3.59200M |
| Operating income | -7.16600M | 1.40M | -0.58500M | 1.47M | 0.98M |
| Other operating expenses | 120.50M | 116.84M | 101.88M | 114.34M | 119.79M |
| Interest expense | 2.25M | 1.54M | 4.83M | 5.41M | 5.37M |
| Tax provision | 0.34M | 0.15M | 0.52M | -0.81500M | -3.67600M |
| Interest income | - | - | - | 5.41M | 5.22M |
| Net interest income | -2.54800M | -1.54000M | -4.83100M | -5.41000M | -5.36700M |
| Extraordinary items | - | - | - | - | 1.38M |
| Non recurring | -0.23300M | - | - | 1.46M | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.34M | 0.15M | 0.52M | -0.81500M | -3.67600M |
| Total revenue | 113.33M | 118.90M | 102.10M | 116.18M | 120.77M |
| Total operating expenses | 67.98M | 65.59M | 57.82M | 62.48M | 62.20M |
| Cost of revenue | 52.52M | 51.25M | 44.06M | 51.85M | 57.59M |
| Total other income expense net | -2.01300M | -1.54000M | -6.70700M | -6.97400M | -4.13200M |
| Discontinued operations | - | - | - | - | 1.38M |
| Net income from continuing ops | -9.51600M | -0.28800M | -7.81000M | -4.68700M | -4.29900M |
| Net income applicable to common shares | -9.51600M | -0.28800M | -7.81000M | -4.68700M | -2.92200M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 137.37M | 145.36M | 162.34M | 156.25M | 164.87M |
| Intangible assets | 16.04M | 21.01M | 27.39M | 33.15M | 38.41M |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.94M | 3.47M | 4.34M | 3.35M | 2.47M |
| Total liab | 64.29M | 73.14M | 78.94M | 79.57M | 83.18M |
| Total stockholder equity | 73.07M | 72.22M | 83.40M | 76.68M | 81.69M |
| Deferred long term liab | - | 0.59M | - | 1.90M | 1.97M |
| Other current liab | 6.00M | 9.62M | 12.90M | 9.59M | 9.12M |
| Common stock | 0.43M | 0.45M | 0.45M | 0.44M | 0.44M |
| Capital stock | 0.43M | 0.45M | 0.45M | 0.44M | 0.44M |
| Retained earnings | -145.60500M | -142.19000M | -132.67400M | -132.38600M | -124.57600M |
| Other liab | - | 1.60M | 8.53M | 12.23M | 2.12M |
| Good will | 57.06M | 56.26M | 57.69M | 58.59M | 57.38M |
| Other assets | - | 7.78M | 12.27M | 8.85M | 2.27M |
| Cash | 4.28M | 4.51M | 7.82M | 8.32M | 8.34M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 26.54M | 23.25M | 25.32M | 21.05M | 25.31M |
| Current deferred revenue | 7.71M | 3.37M | 4.27M | 3.77M | 3.95M |
| Net debt | 38.49M | 42.32M | 40.51M | 39.69M | 45.48M |
| Short term debt | 7.28M | 3.81M | 3.23M | 1.72M | 6.90M |
| Short long term debt | 5.86M | 3.81M | 3.23M | 1.72M | 6.90M |
| Short long term debt total | 42.77M | 46.82M | 48.33M | 48.01M | 53.82M |
| Other stockholder equity | 232.44M | 229.01M | 225.65M | 221.69M | 218.52M |
| Property plant equipment | - | 3.37M | 3.42M | 3.96M | 4.78M |
| Total current assets | 49.04M | 51.12M | 61.58M | 51.70M | 53.57M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 72.22M | 83.40M | -15.06000M | 24.31M |
| Short term investments | - | - | - | - | - |
| Net receivables | 16.10M | 16.70M | 21.83M | 17.77M | 20.70M |
| Long term debt | 30.70M | 43.01M | 45.09M | 46.29M | 46.92M |
| Inventory | 24.72M | 26.44M | 27.59M | 22.26M | 22.06M |
| Accounts payable | 5.55M | 6.45M | 4.91M | 5.97M | 5.34M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -14.19000M | -15.05200M | -10.02700M | -13.06600M | -12.68900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.45M | 0.45M | 0.44M | 0.44M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -142.19000M | -132.67400M | -132.38600M | -124.57600M |
| Treasury stock | - | - | - | -10.66800M | -10.66800M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 6.04M | 13.60M | 12.27M | 8.85M | 10.74M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 88.33M | 94.24M | 100.76M | 104.55M | 111.30M |
| Capital lease obligations | 6.21M | 7.42M | 8.63M | 9.59M | 10.65M |
| Long term debt total | - | - | - | 46.29M | 46.92M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1.59000M | -1.34500M | -1.40200M | -0.22900M | -53.79600M |
| Change to liabilities | -1.93900M | -0.10100M | 0.48M | -3.97200M | -1.31300M |
| Total cashflows from investing activities | -1.59000M | -1.34500M | -1.40200M | -0.22900M | -53.79600M |
| Net borrowings | -1.78600M | -0.05200M | -7.49400M | -7.40300M | 48.50M |
| Total cash from financing activities | -2.83700M | -0.25200M | -7.96700M | -7.62600M | 53.05M |
| Change to operating activities | -0.06600M | -10.19000M | 4.11M | -1.39600M | -6.13400M |
| Net income | -9.51600M | -0.28800M | -7.81000M | -4.68700M | -3.46200M |
| Change in cash | -3.31300M | -0.49600M | -0.01800M | 0.16M | 2.44M |
| Begin period cash flow | 7.82M | 8.32M | 8.34M | 8.17M | 5.73M |
| End period cash flow | 4.51M | 7.82M | 8.32M | 8.34M | 8.17M |
| Total cash from operating activities | 1.15M | 1.26M | 9.33M | 8.05M | 2.34M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 7.58M | 7.62M | 7.63M | 7.73M | 7.88M |
| Other cashflows from investing activities | - | -0.15000M | -0.25000M | 0.99M | -52.81000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 0.25M | -5.86100M | 0.41M | 3.26M | 2.55M |
| Change to account receivables | 4.78M | -4.29400M | 3.10M | 0.47M | -2.79200M |
| Sale purchase of stock | 0.58M | 3.31M | - | -0.22100M | 4.56M |
| Other cashflows from financing activities | 6.17M | 3.95M | 60.84M | 4.30M | 68.69M |
| Change to netincome | 4.41M | 4.17M | 5.15M | 4.97M | -1.04600M |
| Capital expenditures | 1.59M | 1.34M | 1.15M | 1.22M | 0.99M |
| Change receivables | 4.78M | -4.29400M | 3.10M | 0.47M | -2.91600M |
| Cash flows other operating | 1.43M | 5.58M | 5.68M | 5.63M | 5.46M |
| Exchange rate changes | - | - | - | - | 0.30M |
| Cash and cash equivalents changes | -3.27500M | -0.33500M | -0.03800M | 0.19M | 2.44M |
| Change in working capital | 2.72M | -10.19000M | 4.11M | 0.04M | -1.67500M |
| Stock based compensation | 4.41M | 4.17M | 3.65M | 3.03M | 3.04M |
| Other non cash items | -3.62000M | 0.28M | 1.90M | 2.32M | -0.58400M |
| Free cash flow | -0.43800M | -0.08300M | 8.18M | 6.83M | 1.36M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HBIO Harvard Bioscience Inc |
-0.001 0.19% | 0.53 | - | 14.93 | 1.64 | 2.52 | 1.99 | 27.76 |
| ISRG Intuitive Surgical Inc |
-0.54 0.11% | 485.31 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
-1.02 0.83% | 121.48 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
- -% | 243.04 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-0.39 0.24% | 163.49 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
84 October Hill Road, Holliston, MA, United States, 01746
| Name | Title | Year Born |
|---|---|---|
| Mr. James W. Green | Pres, CEO & Chairman | 1958 |
| Mr. Michael A. Rossi | Chief Financial Officer | 1974 |
| Mr. Kenneth Fletcher Olson | Exec. Officer | 1962 |
| Mr. David Balcom | Sr. VP of Operations | NA |
| Mr. John J. Fry | Chief Legal Counsel & Corp. Sec. | 1961 |
| Mr. Ryan Wallace | Sr. VP of Global Sales - Preclinical Systems | NA |
| David Sirois | Director of Corp. Accounting & SEC Reporting | NA |
| Mr. James W. Green | President, CEO & Chairman | 1958 |
| Mr. David Balcom | Senior Vice President of Operations | NA |
| Mr. John J. Fry | Chief Legal Counsel & Corporation Secretary | 1961 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...